IPP Bureau
India achieves significant landmark in reduction of child mortality rates
By IPP Bureau - September 24, 2022
The country has been witnessing a progressive reduction in IMR, U5MR and NMR
19 crore AB-PMJAY cards created; 3.8 crore beneficiaries avails free benefit
By IPP Bureau - September 24, 2022
AB PMJAY has been successful in providing quality health services to the beneficiaries who come from weak financial backgrounds
Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
By IPP Bureau - September 23, 2022
Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US
Shilpa Medicare Hyderabad facility receives US FDA clearance
By IPP Bureau - September 23, 2022
The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties
U.S. District Court rules in favor of Merck in Sitagliptin Phosphate patent lawsuit
By IPP Bureau - September 23, 2022
Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR
Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
By IPP Bureau - September 23, 2022
One in two women with advanced ovarian cancer has an HRD-positive tumor
KRSNAA leverages AI to deliver quality diagnostics to the rural hinterlands of India
By IPP Bureau - September 23, 2022
Krsnaa Diagnostics plans to set up Tele-Pathology Reporting Centre in Pune
Cipla receives EIR for Indore plant, Aurbindo for Raleigh
By IPP Bureau - September 23, 2022
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
KDAH receives SMART ICU certification after pandemic
By IPP Bureau - September 23, 2022
Kokilaben Hospital is also the first hospital in Navi Mumbai to receive the SMART ICU certification
Charsire's new drug aims to capture dementia treatment market
By IPP Bureau - September 22, 2022
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
JB Pharma witness 20% growth in August 2022: IQVIA
By IPP Bureau - September 22, 2022
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Aster Hospitals Bangalore launches 'Aster International Institute of Oncology'
By IPP Bureau - September 22, 2022
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin
By IPP Bureau - September 22, 2022
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Aster Pharmacy forays into Bangladesh
By IPP Bureau - September 22, 2022
Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.
Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
By IPP Bureau - September 22, 2022
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
